Disseminated Mycobacterium immunogenum infection presenting with septic shock and skin lesions in a renal transplant recipient

Mycobacterium immunogenum is a relatively new species within the Mycobacterium chelonae‐Mycobacterium abscessus group of rapidly growing mycobacteria (RGM). M. immunogenum was first characterized in 2001 and, similar to other RGM, is an ubiquitous environmental organism. This organism has most commo...

Full description

Saved in:
Bibliographic Details
Published in:Transplant infectious disease 2012-08, Vol.14 (4), p.415-421
Main Authors: Biggs, H.M., Chudgar, S.M., Pfeiffer, C.D., Rice, K.R., Zaas, A.K., Wolfe, C.R.
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Drug interaction
Fatal Outcome
Humans
Infection
Kidney transplantation
Kidney Transplantation - adverse effects
Male
Microbial Sensitivity Tests
Middle Aged
Mycobacterium
Mycobacterium - classification
Mycobacterium - drug effects
Mycobacterium - genetics
Mycobacterium - isolation & purification
Mycobacterium immunogenum
Mycobacterium Infections, Nontuberculous - microbiology
New species
rapidly growing mycobacteria
renal transplant
Septic shock
Shock, Septic - microbiology
Skin diseases
Skin Diseases, Bacterial - microbiology
Toxicity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mycobacterium immunogenum is a relatively new species within the Mycobacterium chelonae‐Mycobacterium abscessus group of rapidly growing mycobacteria (RGM). M. immunogenum was first characterized in 2001 and, similar to other RGM, is an ubiquitous environmental organism. This organism has most commonly been implicated in cutaneous infection in both healthy and immunosuppressed patients. To our knowledge, this is the first reported case of septic shock in the setting of disseminated M. immunogenum infection. Definitive identification of this organism requires gene sequencing at specialized centers, which may limit its detection. M. immunogenum is resistant to many anti‐mycobacterial agents, and treatment can be especially challenging in transplant patients, given potential drug interactions and added toxicities. It is important to distinguish M. immunogenum from other RGM and determine the susceptibility profile to devise a successful treatment plan, particularly in the transplant population in which it can potentially cause severe, disseminated disease.
ISSN:1398-2273
1399-3062
DOI:10.1111/j.1399-3062.2012.00730.x